为了评估拉坦前列烯布诺(LBN)的比较疗效,一种新型前列腺素类似物(PGA),开角型青光眼和高眼压降低眼压(IOP)的其他药物。
改编自Li等人的系统文献综述(眼科,2016)进行了研究。Medline,检索了Embase和PubMed在2014年1月1日至2020年3月19日之间发表的随机对照试验。研究报告,至少两种不同的安慰剂治疗3个月后IOP降低,PGAs(比马前列素0.01%,比马前列素0.03%,拉坦前列素,LBN,他氟前列素,乌诺前列酮)或阿普拉科尼丁,倍他洛尔,溴莫尼定,布林佐胺,卡替洛尔,多佐胺,左巴诺洛尔,噻吗洛尔,曲伏前列素.进行了贝叶斯网络荟萃分析,以根据IOP降低和排名概率的平均差异(95%可信间隔)提供相对效果。生成累积排序曲线下的表面(SUCRA)。
共有106项试验纳入了18523名参与者的数据。LBN明显比乌诺前列酮更有效(-3.45(-4.77至-2.12))。尽管相对效果并不显著,与其他PGA相比,LBN在数值上优于拉坦前列素(-0.70(-1.83至0.43))和他氟前列素(-0.41(-1.87至1.07)),与比马前列素0.01%(-0.02(-1.59至1.55))相似,比马前列素0.03%(-0.17(-1.42至1.07))略显不利。LBN比β-受体阻滞剂阿伐昔定有效,倍他洛尔,溴莫尼定,布林佐胺,卡替洛尔,多佐胺和噻吗洛尔.根据SUCRA,LBN排名第二,仅次于比马前列素0.03%,其次是比马前列素0.01%。
LBN比PGA乌诺前列酮和大多数β受体阻滞剂更有效。与最广泛使用的PGA相比,LBN在数值上优于拉坦前列素和曲伏前列素,与比马前列素0.01%相似。
To assess the comparative efficacy of latanoprostene bunod (LBN), a novel prostaglandin analogue (PGA), to other medications for open-angle glaucoma and ocular hypertension on lowering intraocular pressure (IOP).
A systematic literature
review adapted from the Li et al (Ophthalmology, 2016) study was conducted. Medline, Embase and PubMed were searched for randomised controlled trials published between 1 January 2014 and 19 March 2020. Studies had to report IOP reduction after 3 months for at least two different treatments among placebo, PGAs (bimatoprost 0.01%, bimatoprost 0.03%,
latanoprost, LBN, tafluprost, unoprostone) or apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide, levobunolol, timolol, travoprost. A Bayesian network meta-analysis was performed to provide the relative effect in terms of mean difference (95% credible interval) of IOP reduction and ranking probabilities. Surface under the cumulative ranking curve (SUCRA) was generated.
A total of 106 trials were included with data for 18 523 participants. LBN was significantly more effective than unoprostone (-3.45 (-4.77 to -2.12)). Although relative effect was not significative, compared with other PGAs, LBN numerically outperformed
latanoprost (-0.70 (-1.83 to 0.43)) and tafluoprost (-0.41 (-1.87 to 1.07)), was similar to bimatoprost 0.01% (-0.02(-1.59 to 1.55)) and was slightly disadvantaged by bimatoprost 0.03% (-0.17 (-1.42 to 1.07)). LBN was significantly more efficient than the beta-blockers apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide and timolol. According to SUCRA, LBN was ranked second after bimatoprost 0.03%, followed by bimatoprost 0.01%.
LBN was significantly more effective than the PGA unoprostone and most of the beta-blockers. Compared with the most widely used PGAs, LBN numerically outperformed
latanoprost and travoprost and was similar to bimatoprost 0.01%.